Basilea Pharmaceutica Reports That Isavuconazole Receives Qualified Infectious Disease Product (QIDP) Designation From U.S. FDA For The Treatment Of Invasive Aspergillosis

BASEL, Switzerland, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.

Help employers find you! Check out all the jobs and post your resume.